The purpose of this study is to evaluate the effectiveness and safety of a home based infusion device for the delivery of a subcutaneous (under the skin) diuretic (Furoscix) in patients with chronic heart failure and fluid overload.

Barostim Neo® - Baroreflex Activation Therapy® for Heart Failure

The study is to evaluate the safe admission avoidance and the overall economic impact associated with management of worsening HF using the drug-device combination product, the Furoscix Infusor, outside the hospital setting in patients initially presenting to the emergency department.